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Abstract
Introduction Mammary stem cells are bipotential and
suggested to be the origin of breast cancer development, but
are elusive and vaguely characterized. Breast tumors can be
divided into subgroups, each one requiring specific treatment.
To determine a possible association between mammary stem
cells and breast cancer, a detailed characterization of the
transcriptome in mammary stem cells is essential.
Methods We have used a murine mammary epithelial stem-like
cell line (HC11) and made a thorough investigation of global
gene-expression changes during stepwise differentiation using
dual-color comparative microarray technique. Subsequently, we
have performed a cross-species comparison to reveal
conserved gene expression between stem cells and subtype-
specific and prognosis gene signatures, and correlated gene
expression to in vivo mammary gland development.
Results Our analysis of mammary stem-like and stepwise cell
differentiation, and an in-depth description of our findings in a
breast cancer perspective provide a unique map of the
transcriptomic changes and a number of novel mammary stem
cell markers. We correlate the alterations to in vivo mammary
gland differentiation, and describe novel changes in nuclear
receptor gene expression. Interestingly, our comparisons show
that specific subtypes of breast cancers with poor prognosis
and metastasizing capabilities show resemblance to stem-like
gene expression.
Conclusions The transcriptional characterization of these
mammary stem-like cells and their differentiation-induced gene
expression patterns is here made widely accessible and
provides a basis for research on mammary stem-like cells. Our
comparisons suggest that some tumors are more stem-like than
others, with a corresponding worse prognosis. This information
would, if established, be important for treatment decisions. We
also suggest several marker candidates valuable to investigate
further.
Introduction
The mammary gland exhibits unique developmental features
during puberty, pregnancy and lactation. For each round of
pregnancy, the mammary gland undergoes sequential cycles
of proliferation, differentiation and apoptosis, and alveolar
ducts form and grow, differentiate to produce milk and, after
lactation, cease, revert and regress to the pre-pregnancy
state. These and several other observations point towards the
presence of stem cells as the basis for the capacity for alveolar
renewal in each pregnancy (reviewed in [1]). These stem cells
would be the origin of the epithelial compartment, where com-
mitted precursor cells become restricted to either a myoepi-
thelial or luminal (ductal or alveolar) fate [1].
The cellular identity and markers of a rapidly cycling population
of normal adult mammary stem cells have been suggested [2].
Some current models explain cancer development by the stem
cell and clonal evolution hypothesis [3]. A bipotential mam-
mary epithelial stem cell and/or a luminal progenitor cell would,
via acquired genetic alterations, epigenetic changes and para-
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crine signals from surrounding cells, abandon its controlled
stem cell self-renewal and develop into a breast tumor cell with
uncontrolled growth [3,4]. Depending on the cell of origin
(stem cell or progenitor cell) and acquired changes, different
forms of breast cancer can develop. Tumors are further
hypothesized to be sustained by the subpopulation of cancer
stem cells [5], which should be specifically targeted for long-
term successful therapeutic intervention.
The only factor known to consistently decrease lifetime breast
cancer risk is early childbirth and breastfeeding [6]. This is
speculated to be due to decreased circulating hormones,
increased differentiation of the mammary cells and/or a
decrease of mammary stem cells in the gland [7]. Exposure to
estrogen is a risk factor for the development of breast cancer.
The effects of estrogens are mediated via two estrogen recep-
tor (ER) isoforms: ERα and ERβ. Activation of ERα drives the
proliferation in most of ERα-positive breast tumors, whereas
ERβ can behave as an antagonist to ERα at the transcriptional
level [8] and may be of protective value in breast cancer. Epi-
demiological studies also suggest that the breast is at partic-
ular risk to acquire deleterious genetic changes before or
during puberty, which is thought to be a period of stem cell
expansion. At this time, exposure to phytoestrogens, ligands of
ERβ, has also been shown to be protective [9].
The overwhelming majority of breast cancers have luminal epi-
thelial characteristics. Five molecular subgroups of breast can-
cer have been defined that can be distinguished according to
their gene expression profiles: basal like, luminal A, luminal C,
Her2+ and normal breast like [10]. Two nuclear receptors,
ERα and its downstream target the progesterone receptor, are
two of the most important prognostic markers of breast can-
cer, whose expression is an indication that anti-estrogenic
therapy can be successful. Most luminal A and luminal C
tumors express these markers, but luminal A tumors have a
considerably better prognosis than luminal C tumors. Most
basal-like, normal breast-like and Her2+  subtypes do not
express ERα; of these subtypes, Her2+ and basal like have a
worse prognosis [10]. There is a need for improved prognostic
markers and tailor-made treatment for each of these groups.
The normal mammary epithelial cell line HC11 originates from
mid-pregnancy BALB/c mice [11], and resembles mammary
stem cells or progenitor cells remarkably. HC11 cells exhibit
both self-renewal and ability for pluripotency: these cells can
be cultured for an unlimited number of passages in a prolifer-
ating stem cell-like phase, they can be made to functionally dif-
ferentiate and express milk proteins in vitro [11] and they can
reconstitute the ductal epithelium of a cleared mammary fat
pad with myoepithelial, alveolar and ductal luminal cells in vivo
[12]. This cell line can be cultured without requirements for
complex exogenously added, without extracellular matrix or
without co-cultivation with other cell types for the prolactin-
dependent in vitro induction of differentiation [11].
Few studies have been performed to investigate the underly-
ing mechanisms when proliferating mammary epithelial cells
differentiate using such pure cell systems of normal stem-like
cells. Desrivières and colleagues have performed initial stud-
ies at the proteome level [13,14] in the HC11 cells, and differ-
ent mammary epithelial subpopulations (basal/myoepithelial,
luminal ERα-positive and luminal ERα-negative) were recently
characterized at the transcriptome level [15]; however, a
broad description of mammary stem cell or stem cell-like tran-
scriptomes and their change during differentiation is lacking.
In vitro models have the benefit of representing homogeneous
cell populations, giving enough material for thorough,
repeated and high-quality analysis, allowing manipulations to
better understand development, characteristics and
responses and minimizing animal use.
In the present study, the undifferentiated stage of the HC11
cells is referred to as stem like, since the cells have the capa-
bility of both self-renewal and pluripotency, but it is not entirely
clear whether the HC11 cells are complete stem cells or are
in the process of becoming progenitor cells. In order to inves-
tigate the transcriptional events behind this stem cell-like state,
to provide a map of mammary epithelial cell differentiation and
to determine a possible connection between mammary stem
cells and breast cancer, we have performed a complete anal-
ysis of all 36,000 known genes and transcripts using dual-
color microarray of the stem cell-like stage and different differ-
entiation stages of these cells. We have compared this stem
cell-like transcriptome with in vivo mammary gland develop-
ment and with gene expression signatures of different types of
human breast cancers and their metastases, and have ana-
lyzed the biological consequences in the context of stem cell
and breast cancer interaction in detail. We report potential
stem-like markers, and show their specificity at the protein
level.
Materials and methods
Cell culture and induction of differentiation
HC11 mammary epithelial cells were routinely grown in com-
plete medium (RPMI 1640, 10% FBS, L-glutamine, 5 μg/ml
insulin, 10 ng/ml epidermal growth factor, and 50 μg/ml gen-
tamicin; all from Sigma, St Louis, MO, USA), and proliferating
cells were obtained under these growth conditions. When
cells reached confluence, the complete medium was changed
to medium without epidermal growth factor (RPMI 1640, 2%
FBS, 5 μg/ml insulin, and 50 μg/ml gentamicin), and pre-dif-
ferentiated (competent) cells were obtained after 48 hours of
growth in this medium. To induce differentiation of competent
cells, cultures were treated for 72 hours with medium without
epidermal growth factor containing 100 nM dexamethasone
and 1 μg/ml ovine prolactin.
Animals and mammary gland tissue
Female Balb/c mice were fed ad libitum and were kept under
a 12-hour light, 12-hour dark cycle. Mammary glands from 2-Available online http://breast-cancer-research.com/content/11/3/R26
Page 3 of 17
(page number not for citation purposes)
month old virgin, 10-day pregnant and 6-day lactation mice
were excised and frozen in liquid nitrogen for RNA extraction.
All animal experimentation was conducted in accordance with
accepted standards of humane animal care as outlined by the
Stockholm South Ethical Committee of the Swedish National
Board for Laboratory Animals.
RNA extraction
RNA was extracted with TRIzol (Invitrogen, Carlsbad, CA,
USA) according to standard protocol, and purified using Qia-
gen RNeasy spin columns (Qiagen, Hilden, Germany) with on-
column DNase I digestion.
Microarray experiment and analysis
Raw data and detailed protocols for the microarray analysis
are available from the ArrayExpress data repository [E-MEXP-
969]. In short, Operon's long-oligonucleotide spotted arrays
covering the whole known genome represented by 36,000
genes and gene transcripts were used (printed by the micro-
array facility at KTH, Royal Institute of Technology, Stockholm,
Sweden). Triplicate cultures of stem-like, pre-differentiated
and differentiated stages of HC11 were analyzed in 10 hybrid-
izations using 20 μg total RNA per sample (20 samples); each
microarray comparison was replicated and dye-swapped with
different sets of cultures to compensate for unequal dye incor-
poration and variance between cultures and differentiations.
Hybridizations were performed in a loop design, where stem-
like stage was hybridized to pre-differentiated stage, pre-differ-
entiated stage to fully differentiated stage and, in addition,
stem-like stage to fully differentiated stage. Scanning was car-
ried out at 10 μm resolution using the G2565BA DNA micro-
array scanner (Agilent Technologies, Santa Clara, CA, USA),
for which the photomultiplier tube was set to 100.
The obtained TIFF images were analyzed using the GenePix
Pro 6 software (Molecular Devices Corp., Union City, CA,
USA), in which TIFF files generated for Cy3 channels and Cy5
channels were superimposed upon each other. Spot identifi-
cation, manual examination of the surface of the array and flag-
ging of spots/regions with poor quality were performed in
GenePix. Result files (gpr files) produced by GenePix were
imported into the R environment for statistical computing and
programming, where data processing and identification of dif-
ferentially expressed genes were carried out using the Biocon-
ductor package bundle, Limma, aroma package and the kth-
package. Unreliable spots with abnormal physical properties
were removed using several filters. After filtering, the slides
were normalized with print-tip loess (local regression) normal-
ization. To identify differentially expressed genes, a parametric
empirical Bayes approach implemented in Limma was used
[16]. This test statistic will assign a score (B-score) to each
gene. The B-score was used to rank the genes so that the
gene with the highest score has the highest probability of
being differentially expressed. When differences were being
investigated, two criteria had to be fulfilled for a gene to be
regarded as differentially expressed: the gene had to have a B-
score of more than 0 and an |M-value| of more than 0.5 (an M-
value is the second logarithm of the fold change).
Genes close to cut-off (B > 0.0, |2logFC| > 0.4 and P  <
0.005) could be confirmed by real-time PCR in three inde-
pendent differentiation cultures. Confirmations of 22 genes
were performed.
Over-representation analysis
Analysis of over-represented themes and classification into
gene ontology functional groups was performed using Expres-
sion Analysis Systematic Explorer [17]. The complete mouse
transcriptome was used to calculate expected frequencies of
over-represented themes. Gene ontology groups were consid-
ered over-represented when the calculated Expression Analy-
sis Systematic Explorer score (modified Fischer Exact
probability test) was ≤ 0.2.
Real-time PCR
cDNA was synthesized with Superscript III (Invitrogen) and
random hexamers using 1 μg DNase-I-treated and purified
RNA. Real-time PCR was performed with SYBR-Green Mas-
termix (Applied Biosystems) according to the manufacturer's
protocol, using 10 ng cDNA per 10 μl reaction in an ABI
PRISM 7500 (Applied Biosystems, Foster City, CA, USA)
under the following conditions: 95°C for 10 minutes, followed
by 40 cycles at 95°C for 15 seconds and 60°C for 40 sec-
onds. All runs were performed in triplicate from triplicate cul-
tures, and specific amplification was checked with melting
curve analysis. Primer sequences of intron-spanning frag-
ments will be provided on request. The ΔCt formula was used
to determine fold-change differences, and 18S was used as
the reference gene.
Western blot
HC11 cells were grown in 10 cm plates and were differenti-
ated as described above. Cells were washed with PBS, col-
lected in a 1.5 ml tube, and pelleted by centrifugation at 4°C
for 2 minutes. The cell pellets underwent one cycle of freeze–
thaw and were resuspended in lysis buffer (1% NP-40, 50 mM
Tris–HCl, pH 7.5, 140 mM NaCl, 2 mM ethylenediamine
tetraacetic acid, 1 mM phenylmethanesulphonylfluoride, 1 mM
Na3VO4 and protease inhibitor cocktail; Roche, Mannheim,
Germany). The lysate was kept on ice for 20 minutes and was
centrifuged at 14,000 rpm for 10 minutes at 4°C. The protein
concentration was determined with Bradford reagent (BioRad,
Hercules, CA, USA). Whole-cell extracts (40 μg protein) were
resolved on SDS-PAGE and transferred onto a Polyvinylidene
Fluoride membrane.
The membranes were blocked with 5% (w/v) milk protein dis-
solved in PBS and were incubated overnight at 4°C with the
following primary antibodies: rabbit anti-ADAMTS1
(GTX11557; Genetex, Irvine, CA, USA), chicken anti-DUSP6Breast Cancer Research    Vol 11 No 3    Williams et al.
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(GTX19115; Genetex), rabbit anti-Birc5 (also known as sur-
vivin, #2808; Cell Signaling, Houston, TX, USA), rabbit anti-
Melk (#2274; Cell Signaling), and mouse anti-COUP TF2
(ab41859; AbCam, Cambridge, UK) and rabbit anti-tubulin
(#2125; Cell Signaling) was used as loading control. The anti-
bodies were considered specific based on previous data and
detection of few bands in the blots, and in all cases the molec-
ular weight of the corresponding bands was calculated using
Quantity One software (BioRad). The secondary antibodies
were coupled to horseradish peroxidase (Sigma). The lumi-
nescent signal was detected with the enhanced chemilumi-
nescence kit (Amersham, Buckinghamshire, UK).
Immunocytochemistry and immunohistochemistry
HC11 cells were cultured on eight-well glass chamber slides
(BD Biosciences, Meylan Cedex, France). Cells were fixed in
10% buffered formalin and permeabilized in 0.5% Triton–PBS
for 30 minutes. Unspecific binding was blocked by incubation
in blocking solution for 1 hour (10% FBS in 0.1% Tween–
PBS). Incubation with the primary antibodies proceeded over-
night at room temperature. The primary antibodies used were
the same as for western blots and also anti-mouse CD44
(#553991; BD Pharmigen, San Diego, CA, USA), mouse anti-
keratin 5/8 (MA1-35858; Affinity Bioreagents, Rockford, IL,
USA) and mouse anti-Rab4 (ab13252; AbCam). After three
washes with PBS, the corresponding secondary antibodies –
anti-mouse-Cy3 (Sigma), anti-rabbit or anti-chicken Alexa 488
(Molecular Probes, Invitrogen, Eugene, OR, USA) and anti-
mouse Alexa 568 (Molecular Probes) – were added (1/500 in
blocking solution) for 1 hour. Cells were washed four times
with PBS and nuclei were stained with ToPro-3 (1/1,000;
Molecular Probes). To assess whether the staining was due to
binding of the primary antibody, a group of samples was
stained in parallel but only with the secondary antibody.
Images were captured using a laser-scanning confocal micro-
scope (Zeiss 510, Stockholm, Sweden). Images were
acquired under the same settings; when edited with Adobe
Photoshop 6.0, the same adjustments were applied to all
images.
Results and discussion
Mammary stem-like cell transcriptome
To explore the largely unknown transcriptome of mammary
stem cells we compared the murine mammary stem-like cells
with their pre-differentiated and fully differentiated stage. In
this way, all changes of genes and important networks for
commitment of cell fate, implementation of differentiation pro-
grams, specification and survival were revealed. The most
highly changed genes, at stem cell-like exit, are presented in
Tables 1 and 2, gene enrichment analysis of over-represented
and under-represented processes is listed in Table 3, and a
schematic overview of changed processes is depicted in Fig-
ure 1. All regulated genes are available in Additional file 1, and
real-time confirmations of 22 genes are available as Additional
files 2 to 4. Confirmations at the protein level are depicted in
Figures 2 to 5.
Our analysis confirmed previous findings, including: an
increase of Stat1 and Stat5a during differentiation, which also
mimics the in vivo control of proliferation, differentiation and
survival during mammary gland differentiation [18]; an
increase of Ctgf expressed, also found in the in vivo mouse
mammary gland during pregnancy and lactation [19]; an
increase of Lamp1, a differentiation marker for HC11 [20]; and
an increase of Igfbp5, whose expression is stimulated during
cellular differentiation by lactogenic hormones [21]. Further, a
decrease of Igfbp2 [21], Hnrpd [22], Cyclin D1 and Myc [23]
during the differentiation of these cells was confirmed. In addi-
tion to the above verifications, which in themselves demon-
strate a high reproducibility of the differentiation process and
of the analysis, a total of 2,251 genes was observed to be
changed in the first step of commitment to differentiation, and
a further 1,010 alterations during the subsequent stage of
functional differentiation. The majority of these alterations are
novel, and the implications of many of them are at this time
unknown.
When cells left the stem-like stage and entered the pre-differ-
entiation stage, gene enrichment analysis of processes – as
defined by the Gene Ontology Consortium – showed that dif-
ferentiation (particularly epithelial differentiation), skeletal
development, cell adhesion, regulation of apoptosis and sev-
eral types of metabolisms (coenzyme, lipid, carbohydrate, oxy-
gen and sulfur metabolism) increased (Figure 1, box A). At the
same time, there was a robust decrease in expression of
mitotic cell cycle-associated genes, metabolism of DNA, RNA,
nucleotide and proteins, respectively, and angiogenesis (Fig-
ure 1, box B). Most genes that were altered in the first transi-
tion remained at this level in the second transition, such as
upregulated genes within vesicle-mediated transport, cell
adhesion and epithelial cell differentiation (Figure 1, box G).
Expression of other genes continued to increase: for example,
skeletal development and positive regulation of transcription
(Figure 1, box E). There was also a significant increase of pro-
tein modifications and additional cell adhesion gene expres-
sion specific for the second transition (Figure 1, box F). The
strong slow-down of proliferation in the first differentiation
transition partially continued in the second differentiation step
(Figure 1, box J – also signified by a strong decrease in prolif-
eration marker Mki67), whereas most of the decreased cell
cycle genes did not change further in the second transition
(Figure 1, box H). Organelle organization, biogenesis, organo-
genesis and regulation of proteolysis and peptidolysis started
to decrease in the second transition (Figure 1, box I). A tempo-
rary increase of 58 genes, pronounced within programmed
cell death genes (Figure 1, box C), and a temporary decrease
of protein metabolism genes (Figure 1, box D) were specific
changes that only occurred in the pre-differentiated stage.Available online http://breast-cancer-research.com/content/11/3/R26
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Among the most strongly altered genes (Tables 1 and 2), tran-
script levels of amino acid phosphorylation proteins (including
Melk) and dephosphorylation proteins (including Dusp6) were
highly elevated at the stem-like cell stage and decreased con-
siderably during differentiation. Melk and Dusp6 expression
was further corroborated at the protein level (Figure 2a, b),
where the decrease upon differentiation was evident. A large
group of different histone transcripts were also found to be
strongly downregulated during differentiation – for example,
Hist1h1a confirmed by real-time PCR (Additional file 2),
Hist1h4h, Hist1h3c and H2afz (Table 1). When differentiation
starts, gene expression of proteinase inhibitor activity (Expi,
confirmed by real-time PCR; Additional file 2), proteolysis pro-
teins (such as cathepsin D and cathepsin A) and transcription-
related proteins (Ehf, confirmed by real-time PCR (Additional
file 2), Plagl1, Stat1, Stat3, Stat5a and Stat6) increased. From
these data we can conclude that the HC11 stem-like cells
have a high activity of cell cycle, protein phosphorylation and
angiogenic activities coupled with low adhesion, apoptosis,
transcriptional activity and differentiation.
Mammary stem cell characteristics in the HC11 stem-like 
cells
The exact features of mammary stem cells are not fully known,
and there are disagreeing reports of mammary stem cell char-
acteristics. Also the exact stem cell characteristics of the cell
line used here are unspecified, but exhibit several trademarks
of stem cells. The HC11 cells are immortal and have the capa-
bility of self-renewal and pluripotency, and maintain properties
that allow them to differentiate in vitro in response to lac-
Figure 1
Schematic overview of mammary stem cell-like cells to differentiation transcriptome transition Schematic overview of mammary stem cell-like cells to differentiation transcriptome transition. Gene categories (as defined by the Gene Ontology 
Consortium) over-represented among differentially expressed genes during the transition from stem-like mammary epithelial cells via pre-differenti-
ated cells to fully differentiated cells. Over-representation analysis was performed using Expression Analysis Systematic Explorer (EASE) software, 
with an EASE score (a conservative adjustment of Fisher's exact probability to weigh significance in favor of gene ontology categories supported by 
many genes) cut-off below 0.02. Boxes A and B denote overall changes between the first and second transitions (stem cell-like stage compared 
with pre-differentiated stage). Boxes C to J denote subgroups where a changed or unchanged value is acquired in the microarray analysis for both 
transitions (stem cell-like stage compared with pre-differentiated stage, as well as pre-differentiated stage compared with fully differentiated stage). 
Number of genes within each group and process are shown within parentheses.Breast Cancer Research    Vol 11 No 3    Williams et al.
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togenic hormones. Their repopulation potential in vivo may not
be perfectly reproducible, however, and the expression of
stem cell markers is not well established. Further, these cells
are proliferating, which our current dogma suggests stem cells
of the mammary gland are not. These cells may be in the proc-
ess of becoming progenitor cells, or they may possibly consti-
tute a mixture of stem and progenitor cells. Regardless, it is of
great interest to define the potential stem-like gene expression
pattern and/or markers for these cells.
To evaluate our material for stem cell characteristics, we com-
pared the gene expression of the stem-like stage with findings
reported or suggested by others. A bipotential human stem
cell is hypothesized to be Cd44+ [3], an adhesion molecule
with roles in signaling, migration and homing. We found that
Cd44 was highly expressed at the stem-like cell stage and
decreased extensively during differentiation at the mRNA level.
Cd44 at the protein level also decreased with differentiation
(Figure 3a), although occasional cells remained positive also
in the differentiated stage. Furthermore, a receptor with similar
properties to Cd44, Hmmr, was strongly overexpressed in the
stem-like stage. A strong correlation with other suggested
mammary stem cell marker genes was observed; that is, Brca1
[24], Krt6, Krt5 [25] and Melk, a suggested stem cell gene in
Figure 2
Protein expression in HC11 stem-like, pre-differentiated and differentiated cells Protein expression in HC11 stem-like, pre-differentiated and differentiated cells. (a) Melk expression analyzed by western blot and immunofluores-
cence. (b) Dusp 6 expression by western blot. (c) COUPTF-II expression by western blot and immunofluorescence. (d) ADAMTS1 expression ana-
lyzed by western blot. *Processed forms of the zymogen. In all cases, whole cell extracts were resolved on 10% SDS-PAGE and membranes blotted 
with the indicated antibodies. Tubulin was used as loading control.Available online http://breast-cancer-research.com/content/11/3/R26
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hematopoietic [26], neural [27] and possibly epidermal stem
cells – the latter two genes were observed and corroborated
also at protein level (Figure 3b and Figure 2a, respectively).
A novel mechanism for the control of stem cell proliferation in
embryonic and neural stem cells involving histone H2afx was
recently described [28]. We found this gene to be overex-
pressed in our stem-like cells. This histone gene has also been
shown to exhibit copy number changes in sporadic breast can-
cer [29]. Vim (vimentin), a suggested stem cell marker in mes-
enchymal cells [30], also showed a decrease during
differentiation (corroborated at protein level; Additional file 6).
Other possible stem cell markers, however, showed an oppo-
site expression in these cells: Lrp5 (a reported cell surface
marker for somatic mammary stem cells), Musashi homolog 2
(Msi2, a neuronal stem cell marker) and both Kit and Kitl (stem
cell markers in hematopoietic stem cells) were all upregulated
at the transcript level during differentiation of HC11 mammary
stem cell-like cells.
Murine mammary stem cells have further been selected using
protein markers CD45/Ptprc-, Ter119/Ly76-, CD31/Pecam1-,
Sca-1/Ly6alow, CD24/Cd24amed  and CD49f/Itga6high  by
Stingl and coworkers [2]. In our HC11 material, however,
these markers were not significantly changed at the transcript
level. One reason for these apparent differences may be that
the protein levels at the cell surface do not always follow the
mRNA levels, so even if the transcript for a specific gene does
not change, other mechanisms can affect both protein locali-
zation and stability. Another reason could be related to where
in the process between pure stem cells towards progenitor
cells our stem-like cells and/or the literature reported cells are
residing. The transcription factor Etv4 (Pea3), suggested to
function in multipotential mammary progenitors to regulate
their lineage-specific differentiation potential by Kurpios and
colleagues [31], was at the highest expression in the stem-like
stage.
HC11 cells have the capacity to differentiate in vivo into both
myoepithelial and luminal (ductal and alveolar) epithelial cells.
Both markers of myoepithelial lineage (Mme/Cd10) and lumi-
nal epithelial lineage (Krt18) increased strongly during differ-
entiation. Further, we compared the expression patterns of the
HC11 cell differentiation stages with the three different mam-
mary epithelial cell subpopulations – basal/myoepithelial, lumi-
nal ERα-positive and luminal ERα-negative – from virgin
mouse mammary gland, characterized at the transcriptome
level in a study by Kendrick and colleagues [15]. Genes spe-
cific for each of the three subgroups were increasing in
expression during differentiation of the HC11 cells, further
proving that all lineages are represented in the differentiated
stage. We found that whereas nearly all luminal specific genes
that were changed during the differentiation of HC11 cells
were upregulated (79 out of 82 for luminal ER-positive and 79
out of 84 for luminal ER-negative), about one-half of the genes
specific for basal/myoepithelial lineage (99 genes) were
upregulated during differentiation, whereas the remaining 91
genes decreased. The reason for this could be that, because
the basal cell layer also contains the mammary epithelial stem
cell compartment [32], and genes in the stem cells should be
downregulated during differentiation, genes in differentiated
cells in the basal/myoepithelial lineage should be correspond-
ingly upregulated during differentiation. The luminal cells
should be mostly represented by differentiated cells, and
genes in these cells would be expected to be upregulated dur-
ing HC11 differentiation.
During midgestational mammary development in vivo, several
signal transducers and activators of transcription are known to
be increased by prolactin; in the HC11 cells, Stat1 (Table 2),
Figure 3
Expression of stem cell markers in HC11 mammary epithelial cells Expression of stem cell markers in HC11 mammary epithelial cells. (a) 
CD44 expression. DIC, differential interference contrast allows visuali-
zation of the cells. Note that the proportion of CD44-positive cells 
decreases as the culture differentiates but the intensity of the signal in 
those cells that are positive remains constant. (b) Keratin 5 and Keratin 
8 (Krt 5/8) expression.Breast Cancer Research    Vol 11 No 3    Williams et al.
Page 8 of 17
(page number not for citation purposes)
Stat3, Stat5a and Stat6 as well as the prolactin-induced pro-
tein increased, indicating that the cells retain this mammary
epithelial cell-differentiation attribute. Furthermore, the milk
protein β-casein was expressed in differentiated cells (Addi-
tional file 7).
Activity of the Wnt, Hedgehog and Notch pathways are other
hallmarks of stem cell characteristics. In the HC11 cells, dras-
tic changes of expression of Wnt members during differentia-
tion was not observed; however, several known positively
regulated Wnt target genes [33] were strongly downregulated
during differentiation (Ccnd1, Birc5, Cd44 and Myc, all cor-
roborated at mRNA and/or protein level (Figures 3 and 4,
Additional file 2), and Cyr61, Fosl1, Cd87/Plaur, Met, Fst,
Emp1, Abcb1b, Ptgs2, Abcb1b, Runx2, Gja1, IL6, Mycbp),
and targets known to be downregulated by Wnt were corre-
spondingly upregulated (Cdh1, confirmed at mRNA level
(Additional file 2), Sox9 and Postn), in agreement with a higher
Wnt activity at the stem-like cell stage. This normal downregu-
lation of the Wnt pathway during differentiation correlates to a
previous report by Shackleton and colleagues showing that
normal differentiation could be inhibited by the over activation
of the Wnt pathway [32]. Several members of the Hedgehog
pathway (including Snail and Prkca) and the Notch pathway
(including Jag1, Jag2, Hr, Lfng, Hes1) were also changed dur-
ing differentiation.
A large study of heterogeneous collections of gene expression
data generated from 83 mouse stem cell-related samples
defined four super-families of stem cell markers associated
with differentiation: serine proteinase inhibitors (serpins), cyto-
chrome P450 family, Rab family GTPases, and nuclear recep-
tors [30]. In HC11 mammary cells, differentially expressed
genes signified all of these four groups. Two serpins (Serpine1
and Serpine2) were highly reduced as the stem-like cells
underwent differentiation. Serpine1 is also involved in regula-
tion of angiogenesis in breast cancer, and Serpine2 in cell dif-
ferentiation. In a previous study of differentiating
hematopoietic stem cells we also identified two serpins as
strongly reduced (Serpin a3g and a3n) [34], of which expres-
sion of Serpina3g has been shown to prevent stem cells from
differentiation [35]. We further found an increase of Group 2
genes (two cytochrome P450 members, Cyp2f2 and Cyp4x1,
in the HC11 cells) and several Rab family GTPases in Group
3 (increase of Rab4a (confirmed at protein level in Figure 5),
Rab1, Rab3a, Rab5b, Rab15, Rab18, Rab25, and related
Figure 4
Expression of Wnt regulated genes in HC11 stem cell-like, pre-differentiated and differentiated cells Expression of Wnt regulated genes in HC11 stem cell-like, pre-differentiated and differentiated cells. Wnt regulated gene expression evaluated by 
western blot and immunofluorescence in HC11 stem cell-like cells, pre-differentiated cells and differentiated cells. Top panel, Birc5; bottom panel, c-
myc. In all cases, whole cell extracts were resolved on 12% SDS-PAGE and membranes were blotted with the indicated antibodies. Tubulin was 
used as loading control.Available online http://breast-cancer-research.com/content/11/3/R26
Page 9 of 17
(page number not for citation purposes)
gene family members Rhoj, Rhoq, Rhou; and decrease of two
Rab family GTPases Rab12 and Rab32) as the mammary
stem-like cells differentiated.
Group 4 (nuclear receptors) was also differentially expressed
in HC11 mammary stem-like cells. Ten nuclear receptors
changed their expression when the mammary stem-like cells
differentiated. COUP-TFII, COUP-TFI, FXRβ, NGFIB, NURR1
and ERβ decreased (Additional file 5). COUP-TFII and COUP-
TFI influence proliferation of breast cancer cells [36,37] and
are implicated in metastasis [38]. In the fly the common ances-
tral gene (svp/NR2F3) regulates stem cell identity of neurob-
lasts [39]. Figure 2c clearly shows the downregulation of
COUP-TFII also at the protein level when the cells start differ-
entiating. Further, RORα, VDR, EAR2 and ERα increased
(Additional file 4). RORα is frequently inactivated in breast
cancers, and VDR is indicated to be protective against breast
cancer [40]. Both COUP-TFII and RORα are among 426
selected markers of stem cells described [30]. Further, we
noted that both ERα and ERβ were among the nuclear recep-
tors that changed during differentiation. Both are involved, in
opposing manners, in mammary development and breast can-
cer [8].
Taken together, a number of stem cell-related changes as well
as changes indicative of a mixture of both myoepithelial and
luminal cell fates are in line with the stem cell characteristics
of these cells.
Mammary stem-like cells show resemblance with breast 
cancer signatures
To investigate whether there are similarities between human
breast cancer gene expression and the stem cell-like expres-
sion of the murine HC11 cells, supporting the hypothesis that
breast cancer primarily arises from mammary stem/progenitor
cells [41], we compared our material of mammary stem-like
gene expression with gene-profiling signatures of breast
tumors. These profiles have a prognostic value equal to or bet-
ter than clinicopathologic variables [42], and a 70-gene signa-
ture is able to distinguish sporadic breast cancer tumors with
poor prognosis from those with favorable prognosis [43].
Comparison showed that the poor prognosis signature over-
lapped with the expression profile of the mammary stem cell-
like genes. In contrast, none of the genes indicating favorable
prognosis were differentially expressed in the stem-like cells
(Table 4).
Among signatures distinguishing subclasses of breast carci-
nomas [10], our stem-like signature showed an irrelevant over-
lap with subclasses nominated as normal breast like, as
luminal epithelial containing ER, and as Her2+. For subtype
luminal C and basal-like tumors, however, there was a consid-
erable overlap of genes (75% and 60%, respectively; see
Table 5). Patients with these two subclasses of breast tumors
also show among the lowest survival [10]. The basal-like phe-
notype has been suggested to resemble normal mammary
stem cells [1,44], which is here demonstrated at the gene
expression level. Both the HC11 cells and the poor-prognosis
and basal-like tumors are characterized by high proliferation;
nonetheless, many of the shared gene signatures are not
Figure 5
Rab4 expression in HC11 stem-like, pre-differentiated and differentiated cells Rab4 expression in HC11 stem-like, pre-differentiated and differentiated cells. Rab4 expression analyzed by immunofluorescence in HC11 stem-like 
cells, pre-differentiated cells and differentiated cells.Breast Cancer Research    Vol 11 No 3    Williams et al.
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directly linked to proliferation but to adhesion (for example,
Tnc, Ly6e, Cdh3), protein phosphorylation (Melk), transcrip-
tion (Id1), development (Ext1) and signal transduction (Ect2,
Gpr126) (Tables 4 to 6).
Our results are in line with the recent report of poorly differen-
tiated aggressive human tumors showing an embryonic stem
cell-like gene expression signature [45]. Here a core set of
nine embryonic transcription regulators was found to be over-
expressed at the mRNA level in many poorly differentiated
tumors, and in the HC11 cells we observed four of these tran-
scription factors to be overexpressed at the stem-like cell
stage (Mybl2, Hmga1, Hmgb3, Tead4). In conclusion, the
comparisons presented here show that breast cancer sub-
types defined by, for example, Sorlie and colleagues [10] can
be further subdivided according to stem cell-like resemblance,
and comparison with both the 70-gene signature, and Sorlie's
classification reveals that stem cell-like expression infers
worse prognosis. We speculate that subtypes with a higher
degree of stem cell-like gene expression may have a higher
fraction of cancer stem cells, yielding a more aggressive can-
cer. Specific markers to determine whether a tumor is stem
Table 1
Mammary stem-like specific gene expression
Symbol Gene 2logFC Gene ontology
Hist1h2bp Histone 1, H2bp -2.78 Nucleosome assembly
Hist1h2bk Histone 1, H2bj -2.95 Nucleosome assembly
Hmmr Hyaluronan-mediated motility receptor -2.85 Not defined
Melk Maternal embryonic leucine zipper kinase -2.68 Protein amino acid phosphorylation
Cbln4 Cerebellin 4 precursor protein -2.38 Not defined
Hist2h2ac Histone 2, H2ac -2.55 Nucleosome assembly
Ccna2 Cyclin A2 -3.21 Regulation of cell cycle
Hist2h3c1 Histone 2, H3c1 -2.91 Nucleosome assembly
Birc5 Baculoviral IAP repeat-containing 5 -2.55 Anti-apoptosis/embryonic development
Exosc6 Exosome component 6 -2.10 rRNA processing
Tmpo Thymopoietin -1.60 Regulation of transcription
Hist1h4h Histone 1, H4h -1.99 Nucleosome assembly
Lig1 Ligase I, DNA, ATP-dependent -1.97 Cell cycle
Dusp6 Dual-specificity phosphatase 6 -2.80 Protein amino acid dephosphorylation
Hist1h3c Histone1, H3c -2.62 Nucleosome assembly
Ckap2 Cytoskeleton-associated protein 2 -1.97 Cell cycle/apoptosis
Adamts1 A disintegrin-like and metalloprotease with thrombospondin type 
1 motif, 1
-2.47 Integrin-mediated signaling pathway/proteolysis
Hist1h4a Histone 1, H4a -2.23 Nucleosome assembly
Mki67 Antigen identified by monoclonal antibody Ki67 -2.00 Cell proliferation
H2afz H2A histone family, member Z -2.53 Nucleosome assembly/multicellular organismal 
development
Cyr61 Cysteine-rich protein 61 -2.89 Regulation of cell growth/cell adhesion
Rrm1 Ribonucleotide reductase M1 -2.44 DNA replication
Hist1h2ag Histone 1, H2ag -2.96 Nucleosome assembly
Lyar Ly1 antibody reactive clone -1.81 Not defined
Ube2c Ubiquitin-conjugating enzyme E2C -1.89 Positive regulation of cell proliferation
Genes highly expressed at the stem-like stage, to decrease upon differentiation. Genes are listed in the order of statistical significance for being 
differentially expressed. 2logFC denotes the 2log of fold-change (a value of -2 equals a fourfold downregulation or a decrease by 75% upon 
differentiation).Available online http://breast-cancer-research.com/content/11/3/R26
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cell-like, of which we here suggest several candidates, could
be important for diagnosis and treatment decisions.
Further, in the transcriptome analysis we observed a relation
between mammary stem-like cell differentiation and regulation
of skeletal development genes (including osteoblastic stem
cell markers Spark and Spp1 [30]). In addition, both Il6, which
functions as a differentiation regulator of preosteoblast cells
[46], and the corresponding downstream osteoblast-specific
differentiation marker Runx2 decreased when stem-like cells
entered differentiation, and Ocil, a negative regulator of oste-
oclast differentiation, showed a robust increase at both differ-
entiation stages. This finding may indicate why breast tumors
have a preference for skeletal metastases, and these genes
may have a potential as metastasis markers. Indeed, other
genes implicated in bone metastasis of breast cancer cells
(Ctfg, Fst and Dusp1 [47] and Adamts1 [47,48]) were altered
during the differentiation of mammary stem-like cells. Expres-
sion of Adamts1 at the protein level is also shown in Figure 2d
as elevated at the stem-like cell stage. In addition, lung metas-
tasis gene expression also has an apparent parallel to stem
cell-like gene expression (Table 6); lung metastasis signature
Table 2
Mammary differentiation specific gene expression
Symbol Gene 2logFC Gene ontology
Expi Extracellular proteinase inhibitor 5.01 Protease inhibitor activity
Gas6 Growth arrest specific 6 3.14 Regulation of cell growth
Slc6a6 Solute carrier family 6, member 6 2.88 Neurotransmitter transport
Ehf Ets homologous factor 3.66 Transcription factor activity
Ctsd Cathepsin D 2.88 Proteolysis
Xdh Xanthine dehydrogenase 1.83 Lactation/regulation of epithelial cell differentiation
D0H4S114 Dna segment, human D4S114 3.32 Regulation of Tgf-b signaling pathway
Nupr1 Nuclear protein 1 1.92 Not defined
H2-T23 Histocompatibility 2, T region locus 23 1.75 Antigen processing and presentation
Atp6v0d1 ATPase, H transporting, V0 subunit D isoform 1 1.78 Proton transport
Cd81 CD 81 antigen 2.03 Positive regulation of cell growth
D12Ertd647e DNA segment, Chr 12, ERATO Doi 647, expressed, transcript 
variant 3
2.22 Not defined
Cbr2 Carbonyl reductase 2 2.92 Metabolic process
Plagl1 Pleiomorphic adenoma gene-like 1 2.43 Positive regulation of transcription from RNA 
polymerase II promoter
Atp6v1a1 ATPase, H transporting, V1 subunit A, isoform 1 1.96 Proton transport
Ctsa Cathepsin A 2.17 Proteolysis
Stat1 Signal transducer and activator of transcription 1 1.56 Transcription
Oas1a 2',5' -Oligoadenylate synthetase 1A 1.61 Negative regulation of viral reproduction
Ddx58 DEAD box polypeptide 58 1.90 Immune response
Tmem154 Transmembrane protein 154 1.76 Not defined
Fcgrt Fc receptor, IgG, alpha chain transporter 1.41 Immune response
Itm2b Integral membrane protein 2B 2.45 Induction of apoptosis
Sema6a Sema domain, transmembrane domain and cytoplasmic 
domain (semaphorin) 6A
1.52 Cell differentiation/apoptosis
Cuedc1 CUE domain containing 1 1.54 Not defined
Rtp4 Receptor transporter protein 4 1.96 Not defined
Genes that increase strongly upon initiation of differentiation. 2logFC denotes the 2log of fold-change (a value of 2 equals a fourfold upregulation 
or a 400% increase during differentiation).Breast Cancer Research    Vol 11 No 3    Williams et al.
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genes [38]) change considerably during differentiation, most
of them being elevated at the stem cell-like stage – for exam-
ple, the cytokine angiopoietin-like 4, shown to prime breast
cancer cells for lung metastasis [49]. The correlation of stem
cell-like gene expression to metastasis signatures may in part
explain the above correlation to poor prognosis.
Our approach using cross-species comparisons of murine
mammary stem cell-like expression and human tumor gene
expression to unlock evolutionarily conserved breast cancer–
stem cell networks has provided highly concordant observa-
tions. Furthermore, this approach recently gained support, as
cross-species comparisons were shown to be a powerful
means of identifying essential connections [50].
Mammary stem-like cell differentiation compared with in 
vivo mammary gland
We were interested to see whether the changes observed
during stem-like cell differentiation showed any resemblance
to the in vivo mammary gland differentiation, keeping in mind
that in the mammary gland the stem cells only constitute a
minority of all cells, and that their gene expression is likely to
be masked by changes in other cells as well as by changes in
the relative proportions of different cell types. The cellular
three-dimensional structure, interaction with stroma and in
vitro versus in vivo signaling, also makes the two systems very
different. We compared mRNA levels of HC11 cells with 2-
month-old virgin, pregnant and lactating mammary glands,
where the proliferating stage could be compared with the
actively proliferating pregnant mammary gland. Genes that
were overexpressed at the stem cell-like stage (Birc5, Areg,
Ereg, Cyclin D, Lif and Hist1h1a) all had increased expression
in the pregnant glands but decreased their expression in the
lactating glands (data available in Additional file 2). For the
genes whose expression was low at the stem cell-like stage
but was upregulated as the cells differentiated, several were
also expressed at a low level in the virgin gland and were
upregulated in pregnant and/or lactating gland (Expi, Ecad,
Perp, Ehf, Nfat), whereas two genes (Msi2h and Mmp15)
showed an opposite regulation and decreased during in vivo
gland differentiation (Additional file 2). Although this compari-
son is relatively simplistic, our data indicate that stem cell-like
proliferation is highest in the pregnant mammary gland
whereas genes robustly expressed at terminal differentiation
of HC11 cells are also highly expressed in the lactating mam-
mary gland.
Table 3
Biological functions over-represented and under-represented in HC11 mammary stem-like cells
No genes EASE score
Over-represented in stem-like cells
Cell cycle 90 3.6 × 10-27
DNA metabolism 72 1.7 × 10-23
RNA metabolism 45 3.2 × 10-12
Regulation of cell cycle 36 1.8 × 10-7
Chromatin assembly/disassembly 14 2.0 × 10-5
Protein amino acid phosphorylation 34 0.008
Protein metabolism 118 0.01
Under-represented in stem-like cells
Coenzyme metabolism 15 0.0003
Cell adhesion 38 0.0007
Vesicle-mediated transport 20 0.003
Lipid metabolism 31 0.004
Epithelial cell differentiation 4 0.005
Regulation of apoptosis 15 0.005
Cell differentiation 19 0.03
Skeletal development 10 0.05
Regulation of transcription, DNA dependent 72 0.13
Biological function as defined by gene ontology. The stem-like cell gene expression is compared with expression in the pre-differentiated stage. 
Expression Analysis Systematic Explorer (EASE) score: modified Fischer exact probability t test.Available online http://breast-cancer-research.com/content/11/3/R26
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Table 4
Correlation of mouse mammary stem-like gene expression and breast tumor prognosis signatures
High at stem-like stage Low at stem-like stage Unchanged
Poor prognosis: 37 genes, 22 of which (59%) changed in stem-like stage
17 genes 5 genes 15 genes
Melk – protein phosphorylation Gpr126 – neuropeptide signaling pathway Tmeff1 – development
Diap3 – cytoskeleton organization Akap2 – unknown function Exoc7 – protein transport
Ext1 – ossification Oxct1 – metabolic process Slc2a3 – transmembrane transport
Ect2 – signaling cascade Fbxo31 – ubiquitin-dependent protein catabolic 
process
Lpcat1 – metabolic process
Uchl5 – ubiquitin-dependent protein catabolic 
process
Igfbp5 – regulation of cell growth Egln1 – oxygen homeostasis
DC13 – unknown function Esm1 – regulation of cell growth Pitrm1 – proteolysis
Gmps – purine base biosynthetic process Cdc42bpa – protein phosphorylation
Dck – pyrimidine nucleotide metabolic process Gpr180 – unknown function
Rcf4 – DNA replication Mmp9 – regulation of apoptosis
Orc6l – DNA replication Hrasls – regulation of cell growth
Dtl – DNA replication Flt1 – regulation of cell proliferation
Cenpa – nucleosome assembly
Prc1 – cell cycle
Ccne2 – cell cycle
Kntc2 – cell cycle
Mcm6 – cell cycle
Nusap1 – cell cycle
Good prognosis: 12 genes, none of which (0%) changed in stem-like stage
0 genes 0 genes 12 genes
Ap2b1 – protein transport
Ms4a7 – signal transduction
Stk32b – protein phosphorylation
Scube2 – calcium ion binding
Aldh4a1 – proline catabolic process
Gstm3 – metabolic process
Peci – metabolic process
Ebf4 – regulation of transcription
Bbc3 – induction of apoptosis
Tgfb3 – cell growth/signal transduction
Fgf18 – regulation of cell proliferation
Wisp1 – regulation of cell growth
From van't Veer et al. [43]. Names and biological process (as defined by gene ontology, selected and/or abbreviated to fit table) are provided.Breast Cancer Research    Vol 11 No 3    Williams et al.
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Table 5
Correlation of mouse mammary stem-like gene expression and breast subtype signatures
High at stem-like stage Low at stem-like stage Unchanged
Normal breast-like (ER-negative): 10 genes, none of which (0%) changed in stem-like stage
0 genes 0 genes 10 genes
Fhl1 – cell differentiation
Cd36 – cell adhesion
Itga7 – cell adhesion
Leprotl1 – unknown
Gpx3 – oxidation reduction
Gpd1 – oxidation reduction
Aoc3 – oxidation reduction
Lpl – lipid catabolic process
Aqp7 – transport
Cidec – apoptosis
Her2+ (ER-negative): four genes, one of which (25%) changed in stem-like stage
1 gene 0 genes 3 genes
Traf4 – regulation of apoptosis Erbb2 – cell proliferation
Grb7 – signal transduction
Smarce1 – chromatin modification
Luminal A (ER-positive, p53 mut): 13 genes, three of which (23%) changed in stem-like stage
0 genes 3 genes 10 genes
ERα – regulation of transcription Gata3 – regulation of transcription
Myo6 – regulation of transcription Foxa1 – regulation of transcription
Xbp1 – regulation of transcription Aff3 – regulation of transcription
Npnt – cell adhesion
Anxa9 – cell – cell adhesion
Gpr160 – signal transduction
Slc39a6 – ion transport
Tff3 – defense response
Acadsb – lipid metabolic process
Nat1 – metabolic process
Luminal C (ER-positive, p53 mut): eight genes, six of which (75%) changed in stem-like stage
5 genes 1 genes 2 genes
Mybl2 – regulation of transcription Ggh – glutamine metabolic process Ywhaz – protein targeting
Ybx1 – transcription Sqle – oxidation reduction
Tfrc – endocytosis
Ebna1bp2 – unknown function
Kif23 – cell cycle
Basal like (ER-negative, p53 mut): 15 genes, nine of which (60%) changed in stem-like stage
5 genes 4 genes 6 genes
Cdh3 – cell adhesion Trim29 – transcription Tnni2 – regulation of transcription
Lamc2 – cell adhesion Slpi – serine – type endopeptidase inhibitor activity Nfib – regulation of transcription
Krt17 – epidermis development Galnt3 – metabolic process Capn6 – proteolysis
Krt5 – epidermis development Sox9 – transcription/regulation of cell proliferation Dmd – peptide biosynthetic process
Cxcl1 – negative regulation of cell proliferation Tgfb2 – apoptosis
Fabp7 – regulation of cell proliferation
From Sorlie et al.[10]. Names and biological process (as defined by gene ontology, selected and/or abbreviated to fit table) are provided. ER, 
estrogen receptor.Available online http://breast-cancer-research.com/content/11/3/R26
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Among the nuclear receptors, we found that COUP-TFII and
NURR1 decreased during differentiation of the HC11 cells
and in the transition from pregnant to lactating mammary
gland. ERβ and VDR, both suggested to be protective in
breast cancer [8,40,51], were further induced in differentiated
(lactating) mammary gland compared with virgin gland,
whereas ERα – which is often increased in breast cancers –
was reduced. Comparison of a published study of in vivo
mouse mammary glands, investigating 10-week nulliparous
mammary glands and 18-day pregnant glands [52], with our
data on HC11 cellular differentiation shows that as many as
279 genes changed in HC11 stem-like cells were also
changed in the pregnant mammary gland, further showing that
there is numerous correlations between the in vitro and in vivo
systems in terms of differentiation.
Conclusions
The aim of the present study was to characterize the differen-
tiation process of the stem cell-like HC11 cell line and to
define the transcriptome of proliferating undifferentiated mam-
mary epithelial stem cell-like cells, in relation to their differenti-
ated counterparts. This provides a basis for research on
mammary stem cells; both known and novel stem cell gene
expression characteristics were found. Characterized mam-
mary stem cell markers are highly needed, and several poten-
tially suitable targets detected in our study will be valuable to
investigate further.
We explored whether there is a link between mammary stem-
like cell gene expression and that of breast cancer. The
present study was performed using an in vitro system of mam-
mary stem-like cell differentiation. In vitro systems have draw-
backs, and rarely fully resemble the in vivo situation, but can
nonetheless yield significant information. We found an inter-
esting correlation between the pattern of stem-like cell expres-
sion and that of human breast cancer with poor prognosis,
metastasis and tumor subtypes. This may indicate that some
breast tumors have a high ratio of cancer stem cells, and may
require specific and aggressive treatment. An amount of novel
gene expression data is presented, with implications for stem
cell and mammary gland development biology and breast can-
cer research. A scheme is provided where key differences
between differentiation steps can be dissected. We conclude
that HC11 cells are relevant for studying mammary stem cells,
their differentiation and their relationship to breast cancer.
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Table 6
Correlation of mouse mammary stem-like gene expression and published breast tumor lung metastasis signatures
Lung metastasis signature: 14 genes, nine of which (64%) changed in stem-like stage
High at stem-like stage (9 genes) Low at stem-like stage (0 genes) Unchanged (5 genes)
Id1 – regulation of transcription Kynu – metabolic process
Tnc – cell adhesion Man1a1 – metabolic process
Ly6ea – cell surface receptor-linked signal transduction Vcam1 – membrane to membrane docking
Ltbp1 – growth factor binding Cxcr4 – apoptosis
Angptl4a – regulation of apoptosis Nedd9 – cell cycle/cell adhesion
Ptgs2 – regulation of cell proliferation
Cxcl1 – negative regulation of cell proliferation
Ereg – regulation of mitosis
Fscn1 – cell proliferation
From Minn et al. [38]. Names and biological process (as defined by gene ontology, selected and/or abbreviated to fit table) are provided. aHigh in 
pre-differentiated stage only.Breast Cancer Research    Vol 11 No 3    Williams et al.
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